WELCOME TO MOST ADVANCED BRANCH OF MEDICINE
DRIVEN BY BASIC PRINCIPLES OF BIOLOGY AND PHYSICS

1. What is Aneurysmal Subarachnoid Hemorrhage (aSAH)?
Aneurysmal subarachnoid hemorrhage is a life-threatening bleed into the space surrounding the brain caused by the rupture of a brain aneurysm (a weakened bulging spot in an artery wall).

2. How common is it?
aSAH affects about 6–16 people per 100,000 annually worldwide. It accounts for roughly 5–10% of all strokes and is more common in women and people aged 40–60.

3. What are the symptoms?
Sudden, severe “thunderclap” headache (worst headache of life), neck stiffness, nausea/vomiting, sensitivity to light, loss of consciousness, seizures, or focal neurological deficits.

4. What are the causes?
Rupture of a saccular aneurysm (often at arterial branch points). Risk factors include smoking, hypertension, family history, connective tissue disorders, and heavy alcohol use.

5. Why is proper diagnosis important?
Early CT or lumbar puncture confirms the bleed; CTA/MRA/DSA identifies the aneurysm. Delayed diagnosis increases risk of re-bleeding, hydrocephalus, and vasospasm, which can cause stroke or death.

6. Complications if left untreated
Re-bleeding (often fatal), hydrocephalus, cerebral vasospasm leading to delayed cerebral ischemia, seizures, and long-term cognitive or physical disability.

7. How will treatment benefit me?
Securing the aneurysm prevents re-bleeding, allows management of complications, and improves survival and functional recovery when performed early at a high-volume center.

8. Treatment options
Endovascular coiling (preferred for most aneurysms), Surgical clipping, Supportive care (blood pressure control, nimodipine, seizure prophylaxis), Endovascular treatment of vasospasm if needed.

9. How should I prepare for the procedure?
NPO (nothing by mouth) after midnight, blood work, medication review (especially antiplatelets/anticoagulants), and transfer to a neurovascular center. The procedure is usually done urgently.

10. The Procedure: Endovascular Coiling for aSAH – what to expect
Under general anesthesia, a catheter is inserted via the groin (or wrist), navigated to the aneurysm under X-ray/DSA guidance, and platinum coils are deployed to pack the aneurysm sac. Procedure typically takes 2–4 hours.

11. What are the risks?
Stroke, aneurysm rupture during procedure, coil migration, groin hematoma, contrast reaction, infection, and radiation exposure. Re-treatment may be needed in some cases.

12. What should I expect after the procedure?
ICU monitoring (often several days), possible external ventricular drain, gradual mobilization, follow-up angiography, and rehabilitation. Hospital stay varies from days to weeks.

13. When should I contact my doctor?
Sudden severe headache, worsening neurological symptoms, fever, seizure, severe neck pain, or signs of infection at the access site.

14. Conclusion
Endovascular coiling is a minimally invasive, effective way to secure a ruptured aneurysm and is the first-line treatment for most patients with aSAH when performed promptly by experienced teams.

1. What is Carotid Artery Stenosis?
Narrowing of the carotid arteries in the neck due to plaque buildup, which reduces blood flow to the brain and raises stroke risk.

2. How common is it?
Affects millions of adults; significant stenosis (>50–70%) is found in ~2–7% of people over 65, higher in those with cardiovascular risk factors.

3. What are the symptoms?
Often asymptomatic (“silent”). When symptomatic: transient ischemic attack (TIA), stroke symptoms (weakness, speech difficulty, vision loss), or carotid bruit on exam.

4. What are the causes?
Atherosclerosis (plaque from cholesterol, smoking, hypertension, diabetes). Other causes include fibromuscular dysplasia or radiation.

5. Why is proper diagnosis important?
Duplex ultrasound, CTA, or MRA quantify stenosis severity and plaque characteristics. Accurate diagnosis guides medical vs. procedural therapy to prevent stroke.

6. Complications if left untreated
Ischemic stroke, TIA, or death from large-vessel occlusion.

7. How will treatment benefit me?
Restores adequate blood flow, significantly reduces future stroke risk (especially when combined with optimal medical therapy), and is less invasive than open surgery for many patients.

8. Treatment options
Best medical therapy (antiplatelets, statins, blood pressure control, lifestyle), Carotid endarterectomy (surgery), Carotid artery stenting (CAS) – minimally invasive endovascular option.

9. How should I prepare for the procedure?
NPO status, blood work, hold blood thinners per protocol, neurological baseline exam, and dual antiplatelet loading (aspirin + clopidogrel).

10. The Procedure: Carotid Artery Stenting – what to expect
Usually under local anesthesia with sedation. Catheter via groin or wrist, embolic protection device deployed, balloon angioplasty, and self-expanding stent placement under fluoroscopy. Takes 1–2 hours.

11. What are the risks?
Stroke/TIA (lower with modern embolic protection), bradycardia, hypotension, groin complications, restenosis, and contrast nephropathy.

12. What should I expect after the procedure?
4–6 hours bed rest, overnight observation, neurological checks, gradual return to activity, and lifelong antiplatelet therapy plus risk factor management.

13. When should I contact my doctor?
Sudden weakness, speech/vision changes, severe headache, groin swelling/bleeding, or fever.

14. Conclusion
Carotid artery stenting is a safe, effective, minimally invasive alternative to surgery for appropriate patients, dramatically lowering stroke risk when combined with medical therapy.

1. What is Carotico-Cavernous Fistula (CCF)?
An abnormal direct connection between the carotid artery (or its branches) and the cavernous sinus venous plexus, causing high-flow shunting.

2. How common is it?
Rare; direct (high-flow) type often traumatic; indirect (low-flow) type more common in older adults, especially postmenopausal women.

3. What are the symptoms?
Pulsatile proptosis (bulging eye), chemosis (red eye), diplopia, orbital bruit, headache, vision loss, or cranial nerve palsies.

4. What are the causes?
Trauma (direct type), spontaneous (indirect type from hypertension or vascular fragility).

5. Why is proper diagnosis important?
CTA, MRA, or DSA confirms the fistula type and drainage pattern. Proper classification guides the safest embolization route and prevents vision loss or intracranial hemorrhage.

6. Complications if left untreated
Vision loss, glaucoma, intracranial hemorrhage, cerebral venous hypertension, or stroke.

7. How will treatment benefit me?
Endovascular embolization cures or controls the fistula in most cases, relieves symptoms, and preserves vision and neurological function.

8. Treatment options
Conservative observation (some indirect low-flow), Endovascular embolization (transarterial, transvenous, or combined) – gold standard, Rarely surgery or radiosurgery.

9. How should I prepare for the procedure?
NPO, blood work, medication review, and baseline ophthalmologic and neurological evaluation.

10. The Procedure: Endovascular Embolization for CCF – what to expect
Under general anesthesia, catheters via groin (arterial and/or venous), coils, liquid embolics, or stents deployed to close the fistula while preserving carotid flow. Duration 2–4 hours.

11. What are the risks?
Stroke, cranial nerve injury, incomplete closure, access-site complications, and radiation exposure.

12. What should I expect after the procedure?
ICU or step-down monitoring, gradual symptom improvement over days to weeks, follow-up angiography, and eye care as needed.

13. When should I contact my doctor?
Worsening vision, severe headache, new neurological deficits, or access-site problems.

14. Conclusion
Endovascular embolization is the mainstay, highly effective treatment for CCF, offering excellent outcomes with a minimally invasive approach.

1. What is Brain Arteriovenous Malformation (AVM)?
A congenital tangle of abnormal blood vessels (arteries connected directly to veins) in the brain that bypasses the capillary bed, creating a high-flow shunt that can rupture and cause bleeding.

2. How common is it?
Occurs in approximately 15 per 100,000 people; most are diagnosed between ages 20–40. They account for about 2% of all strokes.

3. What are the symptoms?
Often asymptomatic until rupture. When symptomatic: sudden severe headache, seizure, focal weakness, speech difficulty, vision changes, or progressive neurological deficits.

4. What are the causes?
Congenital (present at birth). Rarely acquired after trauma or radiation. Risk of rupture increases with size, deep location, and certain venous drainage patterns.

5. Why is proper diagnosis important?
DSA (digital subtraction angiography) is the gold standard. MRI/MRA and CT help define size, location, and associated aneurysms. Accurate Spetzler-Martin grading guides safe treatment planning and prevents hemorrhage.

6. Complications if left untreated
Intracranial hemorrhage (most serious), seizures, progressive neurological deficit, hydrocephalus, and death.

7. How will treatment benefit me?
Complete obliteration eliminates future bleeding risk, controls seizures, and preserves neurological function when achieved safely.

8. Treatment options
Observation (small, unruptured, low-risk), Endovascular embolization (often staged, using liquid embolics), Microsurgical resection, Stereotactic radiosurgery (Gamma Knife, etc.), Combination therapy.

9. How should I prepare for the procedure?
NPO status, blood work, medication review (hold anticoagulants/antiplatelets), baseline neurological exam, and possible steroid premedication.

10. The Procedure: Endovascular Embolization for Brain AVM – what to expect
Under general anesthesia, catheters are advanced via the groin into cerebral arteries under X-ray guidance. Liquid embolic agents (Onyx, glue) are injected to occlude feeding arteries and the nidus. Sessions may last 2–6 hours; multiple staged procedures are common.

11. What are the risks?
Stroke, hemorrhage during embolization, catheter-related complications, incomplete obliteration, radiation exposure, and neurological deficits.

12. What should I expect after the procedure?
ICU monitoring, serial neurological exams, possible steroids for swelling, follow-up angiography in 1–3 months, and gradual return to activity.

13. When should I contact my doctor?
Sudden headache, seizure, new weakness, vision changes, or access-site bleeding.

14. Conclusion
Endovascular embolization is a key minimally invasive tool that can cure or significantly reduce the risk of AVM rupture when performed by experienced neurointerventional teams.

1. What is Dural Arteriovenous Fistula (DAVF)?
An acquired abnormal connection between dural arteries and dural venous sinuses or cortical veins, causing high-pressure shunting.

2. How common is it?
Rare; accounts for 10–15% of intracranial arteriovenous shunts. More common in adults >50 years.

3. What are the symptoms?
Pulsatile tinnitus, headache, seizure, progressive neurological deficits, or signs of intracranial hypertension/hemorrhage.

4. What are the causes?
Often idiopathic or secondary to sinus thrombosis, trauma, surgery, or infection.

5. Why is proper diagnosis important?
DSA is essential to classify drainage pattern (Borden/Cognard). Aggressive drainage into cortical veins carries high hemorrhage risk and requires prompt treatment.

6. Complications if left untreated
Intracranial hemorrhage, venous infarction, seizures, and progressive neurological decline.

7. How will treatment benefit me?
Endovascular cure or disconnection of the shunt eliminates bleeding risk and relieves symptoms.

8. Treatment options
Observation (benign drainage), Endovascular embolization (transarterial, transvenous, or combined) – preferred, Surgery or radiosurgery in selected cases.

9. How should I prepare for the procedure?
NPO, blood work, medication review, and neurological baseline.

10. The Procedure: Endovascular Embolization for DAVF – what to expect
General anesthesia; arterial and/or venous access via groin. Coils, liquid embolics, or stents used to disconnect the fistula under fluoroscopy. Duration 2–5 hours.

11. What are the risks?
Stroke, cranial nerve injury, incomplete closure, access complications, and radiation.

12. What should I expect after the procedure?
Overnight or ICU monitoring, symptom improvement over days–weeks, follow-up angiography.

13. When should I contact my doctor?
Worsening symptoms, new deficits, or access-site issues.

14. Conclusion
Endovascular embolization offers high cure rates with a minimally invasive approach for most symptomatic or high-risk DAVFs.

1. What is Juvenile Nasopharyngeal Angiofibroma (JNA)?
A benign but locally aggressive vascular tumor occurring almost exclusively in adolescent males, arising in the nasopharynx and extending into surrounding sinuses and skull base.

2. How common is it?
Rare (0.5–1 per 100,000); almost exclusively in males aged 10–25.

3. What are the symptoms?
Recurrent epistaxis, nasal obstruction, facial swelling, headache, and proptosis or cranial nerve involvement in advanced cases.

4. What are the causes?
Hormonal influence (androgen-sensitive); exact etiology unclear.

5. Why is proper diagnosis important?
CT and MRI define extent; DSA with embolization planning is critical before surgery to reduce blood loss.

6. Complications if left untreated
Massive hemorrhage, airway obstruction, intracranial extension, and facial deformity.

7. How will treatment benefit me?
Pre-operative embolization dramatically reduces intraoperative bleeding, enabling safer complete surgical resection.

8. Treatment options
Endoscopic or open surgical resection (after embolization), Pre-operative endovascular embolization (main IR role), Radiation or chemotherapy in unresectable/recurrent cases.

9. How should I prepare for the procedure?
NPO, blood work, type-and-cross, and ENT/neurosurgical coordination.

10. The Procedure: Pre-operative Embolization for JNA – what to expect
General anesthesia; femoral access, selective catheterization of feeding arteries (usually from external carotid branches), and particle or liquid embolization. Takes 1–3 hours, performed 24–48 hours before surgery.

11. What are the risks?
Stroke (rare), facial nerve injury, skin necrosis, incomplete embolization, and access complications.

12. What should I expect after the procedure?
Overnight observation, possible mild facial pain/swelling, and proceeding to surgery the next day.

13. When should I contact my doctor?
Severe bleeding, neurological changes, or access-site problems.

14. Conclusion
Pre-operative embolization is a standard, highly effective adjunct that makes surgical removal of JNA safer and more complete.

1. What is Vertebral Compression Fracture?
Collapse of a vertebral body, most commonly due to osteoporosis, trauma, or tumor infiltration.

2. How common is it?
Affects ~700,000 people annually in the U.S.; very common in postmenopausal women and older adults.

3. What are the symptoms?
Sudden back pain (often after minor trauma), height loss, kyphosis, and limited mobility.

4. What are the causes?
Osteoporosis (most common), malignancy (metastasis or myeloma), trauma, or osteonecrosis.

5. Why is proper diagnosis important?
MRI distinguishes acute from chronic fractures and identifies tumor involvement. Proper patient selection maximizes pain relief from vertebroplasty/kyphoplasty.

6. Complications if left untreated
Chronic pain, progressive kyphosis, reduced pulmonary function, and increased risk of subsequent fractures.

7. How will treatment benefit me?
Rapid and significant pain relief, improved mobility, and stabilization of the vertebra with minimal downtime.

8. Treatment options
Conservative (bracing, pain meds, physical therapy), Vertebroplasty / Kyphoplasty (cement augmentation), Surgery (in select unstable or neurologic cases).

9. How should I prepare for the procedure?
NPO, blood work (coagulation), medication review, and recent imaging review.

10. The Procedure: Vertebroplasty – what to expect
Local anesthesia ± sedation. Needle inserted percutaneously into the vertebral body under fluoroscopy; bone cement injected. Takes 30–60 minutes per level.

11. What are the risks?
Cement leakage (usually asymptomatic), infection, bleeding, fracture of adjacent vertebrae, and rare pulmonary embolism of cement.

12. What should I expect after the procedure?
4–6 hours bed rest, rapid pain improvement (often within hours), and discharge same or next day with activity as tolerated.

13. When should I contact my doctor?
Severe new pain, fever, leg weakness/numbness, or signs of infection.

14. Conclusion
Vertebroplasty/kyphoplasty is a safe, minimally invasive procedure that provides fast, durable pain relief for appropriately selected patients with painful vertebral compression fractures.

1. What is Dialysis Fistula / Graft Dysfunction?
Dialysis fistulas and grafts are surgically created connections between an artery and vein (or a synthetic tube) that allow repeated access for hemodialysis. Dysfunction occurs when these accesses narrow, clot, or fail to maintain adequate blood flow for effective dialysis.

2. How common is it?
Very common in dialysis patients; up to 50% of fistulas/grafts require intervention within the first year due to stenosis or thrombosis.

3. What are the symptoms?
Difficulty with dialysis (high pressures, poor flow), arm swelling, prolonged bleeding after needle removal, pulsatile mass, or reduced dialysis efficiency.

4. What are the causes?
Neointimal hyperplasia causing stenosis, thrombosis, infection, or mechanical issues. Risk factors include diabetes, smoking, and prior access failures.

5. Why is proper diagnosis important?
Ultrasound, fistulography, or angiography identifies the exact site and cause of dysfunction. Timely intervention prevents access loss and the need for temporary catheters.

6. Complications if left untreated
Complete access thrombosis, infection, inadequate dialysis leading to fluid overload or toxin buildup, and loss of the access site.

7. How will treatment benefit me?
Restores or improves blood flow, allows continued effective dialysis, prolongs the life of the access, and avoids more invasive surgical revisions.

8. Treatment options
Observation or medical management for mild cases, Endovascular interventions (angioplasty, stenting, thrombolysis, mechanical thrombectomy) – preferred minimally invasive options, Surgical revision or new access creation.

9. How should I prepare for the procedure?
NPO status, blood work (including coagulation), hold blood thinners per instructions, and inform the team of allergies or recent illnesses. Often performed as outpatient.

10. The Procedure: Dialysis Fistula/Graft Declotting and Interventions – what to expect
Local anesthesia ± sedation. Ultrasound and fluoroscopy guidance. A small sheath is placed into the access, followed by angioplasty balloon, stent if needed, or devices/medications to remove or dissolve clot. Procedure usually takes 1–2 hours.

11. What are the risks?
Bleeding/bruising at access site, infection, vessel injury, restenosis, allergic reaction to contrast, and rarely vessel rupture.

12. What should I expect after the procedure?
Pressure at the site for bleeding control, observation for a few hours, possible same-day discharge. Avoid heavy lifting/strenuous activity for 24 hours. Follow-up dialysis and ultrasound monitoring.

13. When should I contact my doctor?
Signs of bleeding, swelling, redness, fever, arm pain/swelling, or problems during next dialysis session.

14. Conclusion
Image-guided endovascular interventions by interventional radiologists are highly effective, minimally invasive ways to restore dialysis access function quickly and safely.

1. What is Deep Vein Thrombosis (DVT)?
A blood clot that forms in a deep vein, most commonly in the legs, which can block blood return to the heart and risk breaking off to cause pulmonary embolism.

2. How common is it?
Affects up to 900,000 Americans each year; incidence rises with age, hospitalization, surgery, cancer, and immobility.

3. What are the symptoms?
Leg swelling, pain, warmth, redness, or heaviness. Many cases are asymptomatic until complications arise.

4. What are the causes?
Virchow’s triad: stasis (immobility, heart failure), endothelial injury (surgery, trauma), and hypercoagulability (cancer, pregnancy, genetic factors, smoking, oral contraceptives).

5. Why is proper diagnosis important?
Duplex ultrasound confirms the diagnosis. Early treatment prevents clot extension, embolization to lungs, and post-thrombotic syndrome (chronic leg pain/swelling).

6. Complications if left untreated
Pulmonary embolism (potentially fatal), recurrent DVT, chronic venous insufficiency, and skin ulcers.

7. How will treatment benefit me?
Dissolves or removes the clot, restores blood flow, reduces acute symptoms, and lowers long-term complications when combined with anticoagulation.

8. Treatment options
Anticoagulation (blood thinners) – mainstay, Catheter-directed thrombolysis or mechanical thrombectomy (for extensive or limb-threatening DVT), Inferior vena cava (IVC) filter in select cases, Compression stockings and lifestyle measures.

9. How should I prepare for the procedure?
NPO, blood work, hold certain medications, and hospital admission for monitoring (especially with thrombolysis).

10. The Procedure: Catheter-Directed Thrombolysis/Thrombectomy for DVT – what to expect
Local anesthesia ± sedation in IR suite. Catheter inserted via groin or arm vein under ultrasound/fluoroscopy, advanced to the clot, and medication delivered or mechanical device used to break up/remove clot. Procedure may take 1–several hours; infusion can continue over 24–72 hours in some cases.

11. What are the risks?
Bleeding (including rare intracranial), infection, vessel damage, allergic reaction, and clot migration.

12. What should I expect after the procedure?
Bed rest initially, close monitoring (often in hospital), transition to oral anticoagulants, compression therapy, and follow-up imaging.

13. When should I contact my doctor?
Sudden shortness of breath, chest pain, severe bleeding, worsening leg swelling/pain, or signs of infection.

14. Conclusion
Catheter-directed therapies offer targeted, minimally invasive clot removal for selected patients with DVT, complementing anticoagulation and improving outcomes.

1. What is Acute Limb Ischemia (ALI)?
Sudden decrease in blood flow to a limb (usually leg or arm) due to embolism or thrombosis, threatening tissue viability.

2. How common is it?
Occurs in ~1–2 per 10,000 people per year; more frequent in older adults with atrial fibrillation or peripheral artery disease.

3. What are the symptoms?
Sudden onset of the “6 Ps”: pain, pallor, paresthesia, paralysis, pulselessness, and poikilothermia (cold limb).

4. What are the causes?
Cardiac emboli (atrial fibrillation), thrombosis on underlying atherosclerosis, trauma, or hypercoagulable states.

5. Why is proper diagnosis important?
Clinical exam + CT angiography or catheter angiography confirms the site and extent. Rapid intervention prevents amputation and limb loss.

6. Complications if left untreated
Tissue necrosis, gangrene, amputation, and systemic complications (sepsis, renal failure).

7. How will treatment benefit me?
Rapid restoration of blood flow saves the limb, relieves pain, and prevents permanent disability when performed within hours.

8. Treatment options
Anticoagulation and supportive care, Catheter-directed thrombolysis or mechanical thrombectomy/embolectomy, Surgical embolectomy or bypass in selected cases, Amputation as last resort.

9. How should I prepare for the procedure?
Urgent evaluation, NPO, blood work, and anticoagulation. Often requires hospitalization.

10. The Procedure: Endovascular Revascularization for ALI – what to expect
Local or general anesthesia. Access via groin, catheter navigation under fluoroscopy, aspiration, mechanical devices, or thrombolysis to clear the occlusion. Duration varies (1–3+ hours).

11. What are the risks?
Bleeding, vessel injury, distal embolization, infection, contrast nephropathy, and reperfusion injury.

12. What should I expect after the procedure?
ICU or step-down monitoring, serial exams of the limb, anticoagulation, wound care if needed, and rehabilitation.

13. When should I contact my doctor?
Worsening pain, color/temperature changes in the limb, bleeding, or fever.

14. Conclusion
Endovascular techniques provide rapid, minimally invasive limb salvage for acute limb ischemia when time is critical.

1. What is Pulmonary Embolism (PE)?
A pulmonary embolism is a blockage in one of the pulmonary arteries in the lungs, usually caused by a blood clot that travels from the legs or other parts of the body (deep vein thrombosis).

2. How common is it?
PE affects hundreds of thousands of people in the U.S. each year and is a leading cause of cardiovascular death. It is more common in hospitalized or immobilized patients.

3. What are the symptoms?
Sudden shortness of breath, chest pain (especially with breathing), coughing (sometimes with blood), rapid heart rate, lightheadedness, or fainting.

4. What are the causes?
Blood clots from deep veins (DVT), immobility, surgery, cancer, pregnancy, smoking, oral contraceptives, or genetic clotting disorders.

5. Why is proper diagnosis important?
CT pulmonary angiography or V/Q scan confirms the diagnosis. Early detection allows anticoagulation or advanced therapies to prevent right heart strain or recurrent emboli.

6. Complications if left untreated
Right heart failure, recurrent PE, pulmonary hypertension, or death.

7. How will treatment benefit me?
Dissolves or removes the clot, restores lung blood flow, relieves symptoms, and reduces mortality risk when performed promptly.

8. Treatment options
Anticoagulation (blood thinners) – first-line, Catheter-directed thrombolysis or mechanical thrombectomy (for massive/submassive PE), Systemic thrombolysis in select cases, IVC filter in patients who cannot receive anticoagulation.

9. How should I prepare for the procedure?
NPO status, blood work, hold certain medications, and hospital admission for monitoring.

10. The Procedure: Catheter-Directed Therapy for PE – what to expect
Local anesthesia ± sedation. Catheter inserted via groin or neck vein under ultrasound/fluoroscopy, advanced to the pulmonary arteries, and medication or mechanical devices used to dissolve/remove clot. Duration 1–several hours.

11. What are the risks?
Bleeding (including intracranial), vessel injury, infection, contrast reaction, and clot migration.

12. What should I expect after the procedure?
ICU monitoring, transition to anticoagulants, oxygen support as needed, and follow-up imaging.

13. When should I contact my doctor?
Worsening shortness of breath, chest pain, bleeding, or signs of infection.

14. Conclusion
Catheter-directed therapies offer targeted, minimally invasive clot treatment for selected patients with life-threatening pulmonary embolism.

1. What is Trigeminal Neuralgia (TN)?
A chronic pain condition causing sudden, severe, electric-shock-like pain in the face due to irritation or compression of the trigeminal nerve.

2. How common is it?
Affects about 4–13 per 100,000 people per year; more common in women and older adults.

3. What are the symptoms?
Brief, intense, stabbing or shock-like facial pain triggered by touching the face, chewing, talking, or brushing teeth. Pain episodes last seconds to minutes.

4. What are the causes?
Blood vessel compression of the nerve (most common), multiple sclerosis, tumors, or nerve damage. Often idiopathic.

5. Why is proper diagnosis important?
MRI rules out secondary causes (tumor, MS). Accurate diagnosis guides medical vs. interventional/surgical therapy and avoids unnecessary treatments.

6. Complications if left untreated
Chronic pain, depression, weight loss from eating difficulty, and reduced quality of life.

7. How will treatment benefit me?
Procedures such as percutaneous radiofrequency ablation (rhizotomy) provide long-term pain relief with minimal invasiveness for medication-refractory cases.

8. Treatment options
Medications (carbamazepine, oxcarbazepine) – first-line, Percutaneous procedures (radiofrequency rhizotomy, glycerol injection, balloon compression), Microvascular decompression (surgery), Stereotactic radiosurgery (Gamma Knife).

9. How should I prepare for the procedure?
NPO status, medication review, and baseline neurological/pain assessment. Usually performed under sedation or anesthesia.

10. The Procedure: Percutaneous Radiofrequency Rhizotomy for TN – what to expect
Local anesthesia with sedation. A needle is inserted through the cheek under X-ray guidance into the foramen ovale at the skull base. Electrode heats the nerve root to create a controlled lesion. Procedure takes 30–60 minutes.

11. What are the risks?
Facial numbness, corneal sensory loss, anesthesia dolorosa, infection, bleeding, and pain recurrence.

12. What should I expect after the procedure?
Immediate or gradual pain relief, facial numbness (expected), short observation period, and discharge same day. Pain may return over years.

13. When should I contact my doctor?
Severe facial numbness affecting eye, new neurological symptoms, infection signs, or return of severe pain.

14. Conclusion
Percutaneous radiofrequency rhizotomy is a safe, effective, minimally invasive option that provides durable pain relief for many patients with trigeminal neuralgia.

1. What is Radiofrequency Ablation (RFA) for Liver Tumors?
A minimally invasive procedure that uses heat generated by high-frequency electrical currents to destroy cancerous or benign liver tumors.

2. How common is it?
RFA is widely used for small liver tumors (typically <3–5 cm), especially hepatocellular carcinoma (HCC) and metastases when surgery is not feasible.

3. What are the symptoms?
Often none until advanced; may include abdominal pain, weight loss, jaundice, or fatigue in liver cancer.

4. What are the causes?
Primary liver cancer (HCC from cirrhosis/hepatitis) or metastases from colorectal, breast, or other cancers.

5. Why is proper diagnosis important?
CT, MRI, or ultrasound confirms tumor size, number, and location. Proper selection ensures complete ablation and optimal outcomes.

6. Complications if left untreated
Tumor growth, liver failure, metastasis, and reduced survival.

7. How will treatment benefit me?
Destroys tumors locally with minimal damage to healthy tissue, extends survival, preserves liver function, and offers shorter recovery than surgery.

8. Treatment options
Surgical resection (when feasible), RFA or Microwave Ablation (MWA) – image-guided thermal ablation, Transarterial therapies (TACE, radioembolization), Systemic therapy or transplantation.

9. How should I prepare for the procedure?
NPO status, blood work (coagulation, liver function), medication review, and recent imaging.

10. The Procedure: RFA for Liver Tumors – what to expect
Local anesthesia ± sedation or general anesthesia. Under CT/ultrasound guidance, a needle-like electrode is inserted through the skin into the tumor. Radiofrequency energy heats and destroys the tumor (usually 10–30 minutes per lesion).

11. What are the risks?
Bleeding, infection, liver abscess, bile duct injury, skin burns, and incomplete ablation.

12. What should I expect after the procedure?
Overnight observation, pain control, possible mild fever, and follow-up CT/MRI in 4–6 weeks to assess response. Most patients resume normal activity within days.

13. When should I contact my doctor?
Severe abdominal pain, fever, jaundice, bleeding, or shortness of breath.

14. Conclusion
Radiofrequency ablation is a safe, effective, minimally invasive treatment for selected liver tumors, offering excellent local control with rapid recovery.

1. What is Gastric Variceal Bleeding (treated via BRTO)?
Gastric varices are dilated veins in the stomach due to portal hypertension; BRTO is a procedure that occludes the outflow shunt and obliterates the varices using a balloon catheter and sclerosant.

2. How common is it?
Gastric varices occur in 10–30% of patients with portal hypertension; bleeding risk is lower than esophageal varices but can be life-threatening when it occurs.

3. What are the symptoms?
Hematemesis (vomiting blood), melena (black stools), abdominal pain, or signs of shock in acute bleeding.

4. What are the causes?
Portal hypertension from cirrhosis, portal vein thrombosis, or splenic vein thrombosis leading to portosystemic shunts.

5. Why is proper diagnosis important?
Endoscopy and CT/MR angiography map the varices and shunt anatomy. BRTO is ideal for isolated gastric varices with gastrorenal shunts.

6. Complications if left untreated
Recurrent massive bleeding, hypovolemic shock, and death.

7. How will treatment benefit me?
Controls acute bleeding, prevents re-bleeding, and avoids the high mortality of untreated gastric variceal hemorrhage.

8. Treatment options
Endoscopic therapies (banding, glue injection), BRTO (balloon-occluded retrograde transvenous obliteration) – highly effective for gastrorenal shunt varices, TIPS (transjugular intrahepatic portosystemic shunt), Beta-blockers and non-selective vasoconstrictors.

9. How should I prepare for the procedure?
NPO, blood work, coagulation correction, antibiotics, and pre-procedure imaging review.

10. The Procedure: BRTO – what to expect
General or local anesthesia. Femoral or jugular vein access; balloon catheter advanced to the gastrorenal shunt under fluoroscopy. Balloon inflated, sclerosant injected to obliterate varices while preserving portal flow. Procedure takes 1–3 hours.

11. What are the risks?
Balloon rupture, sclerosant leakage, portal vein thrombosis, infection, and transient worsening of esophageal varices.

12. What should I expect after the procedure?
Overnight monitoring, possible transient abdominal pain or fever, follow-up endoscopy/imaging, and continued management of portal hypertension.

13. When should I contact my doctor?
Recurrent bleeding, severe abdominal pain, fever, or leg swelling.

14. Conclusion
BRTO is a highly effective, minimally invasive endovascular treatment that achieves excellent control of gastric variceal bleeding with low re-bleeding rates.

1. What is Microwave Ablation (MWA) for Liver / Kidney Tumors?
A minimally invasive procedure that uses microwave energy to generate heat and destroy cancerous or benign tumors in the liver or kidney.

2. How common is it?
Widely used for small tumors (typically <4–5 cm) when surgery is not ideal; very common for hepatocellular carcinoma (HCC) and renal cell carcinoma.

3. What are the symptoms?
Often none in early stages; may include flank or abdominal pain, blood in urine (kidney), weight loss, or fatigue.

4. What are the causes?
Primary cancers (HCC, renal cell carcinoma) or metastases; risk factors include cirrhosis, hepatitis, smoking, and family history.

5. Why is proper diagnosis important?
CT, MRI, or ultrasound confirms tumor size, location, and number. Proper selection maximizes complete tumor destruction while protecting healthy tissue.

6. Complications if left untreated
Tumor growth, organ dysfunction, metastasis, and reduced survival.

7. How will treatment benefit me?
Destroys tumors locally with minimal damage to surrounding tissue, preserves organ function, short recovery time, and can be repeated if needed.

8. Treatment options
Surgical resection (when feasible), Microwave or radiofrequency ablation, Cryoablation, Embolization or systemic therapies.

9. How should I prepare for the procedure?
NPO status, blood work (coagulation, kidney/liver function), medication review, and recent imaging.

10. The Procedure: Microwave Ablation – what to expect
Local anesthesia ± sedation or general anesthesia. Under CT/ultrasound guidance, a thin antenna is inserted through the skin into the tumor. Microwave energy is applied (usually 5–15 minutes per lesion) to heat and destroy the tumor.

11. What are the risks?
Bleeding, infection, organ injury, skin burns, incomplete ablation, and damage to nearby structures (bile ducts, bowel, etc.).

12. What should I expect after the procedure?
Overnight observation, pain control, possible mild fever, and follow-up imaging in 4–6 weeks. Most patients resume normal activity within a few days.

13. When should I contact my doctor?
Severe pain, fever, bleeding, jaundice (liver), or blood in urine (kidney).

14. Conclusion
Microwave ablation is a safe, effective, minimally invasive option for treating liver and kidney tumors with excellent local control and rapid recovery.

1. What is Portal Vein Embolization (PVE)?
A procedure that intentionally blocks blood flow to a portion of the liver (usually the right lobe) before major liver surgery, causing the remaining liver to grow and regenerate.

2. How common is it?
Standard pre-operative step for patients needing extensive liver resection (e.g., for colorectal metastases or large tumors) when future liver remnant is too small.

3. What are the symptoms?
Usually none; performed electively in patients with planned major hepatectomy.

4. What are the causes?
Underlying liver tumors or metastases requiring large-volume liver removal.

5. Why is proper diagnosis important?
CT volumetry assesses future liver remnant size. PVE is indicated when the remnant is <20–30% of total liver volume.

6. Complications if left untreated
Inadequate liver regeneration after surgery leading to liver failure.

7. How will treatment benefit me?
Increases the size of the healthy future liver remnant, allowing safer major liver resection with lower risk of postoperative liver failure.

8. Treatment options
PVE (percutaneous, transhepatic approach) – most common, Surgical ligation (less common), Associating liver partition and portal vein ligation (ALPPS) in selected cases.

9. How should I prepare for the procedure?
NPO, blood work (coagulation, liver function), recent CT volumetry, and medication review.

10. The Procedure: Portal Vein Embolization – what to expect
Local anesthesia ± sedation. Under ultrasound/fluoroscopy, a needle is inserted through the skin into the portal vein. Embolic material (particles, coils, glue) is delivered to occlude the targeted portal branches. Procedure takes 1–2 hours.

11. What are the risks?
Bleeding, infection, portal vein thrombosis, non-target embolization, and transient liver enzyme elevation.

12. What should I expect after the procedure?
Overnight observation, mild discomfort, follow-up CT volumetry in 3–6 weeks to confirm liver growth, then proceed to surgery.

13. When should I contact my doctor?
Severe abdominal pain, fever, jaundice, or bleeding at the puncture site.

14. Conclusion
Portal vein embolization is a safe, minimally invasive procedure that safely enables major liver surgery by promoting regeneration of the future liver remnant.

1. What is Transarterial Chemoembolization (TACE)?
A minimally invasive procedure that delivers chemotherapy directly to liver tumors via the hepatic artery, followed by embolization to block blood supply and trap the drug inside the tumor.

2. How common is it?
One of the most common treatments for intermediate-stage hepatocellular carcinoma (HCC) and some liver metastases.

3. What are the symptoms?
Often none early; later: abdominal pain, weight loss, jaundice, ascites, or fatigue.

4. What are the causes?
Cirrhosis (hepatitis B/C, alcohol, NASH), aflatoxin exposure, or genetic factors for HCC.

5. Why is proper diagnosis important?
Multiphasic CT/MRI confirms tumor size, number, vascularity, and liver function (Child-Pugh score). Proper staging guides TACE versus other therapies.

6. Complications if left untreated
Tumor progression, liver failure, and reduced survival.

7. How will treatment benefit me?
Delivers high-dose chemotherapy locally while cutting off tumor blood supply, leading to tumor shrinkage or necrosis with fewer systemic side effects.

8. Treatment options
TACE (conventional or drug-eluting beads), Radioembolization (Y-90), Ablation (RFA/MWA), Systemic therapy or liver transplant.

9. How should I prepare for the procedure?
NPO, blood work (liver/kidney function, coagulation), antibiotics, and recent imaging.

10. The Procedure: TACE – what to expect
Local anesthesia ± sedation. Catheter via groin into the hepatic artery under X-ray guidance. Chemotherapy mixed with embolic particles is injected directly into tumor-feeding arteries. Procedure takes 1–3 hours.

11. What are the risks?
Post-embolization syndrome (fever, pain, nausea), liver failure, infection, bile duct injury, and non-target embolization.

12. What should I expect after the procedure?
Hospital stay (usually 1–3 days), pain/fever management, and follow-up imaging in 4–6 weeks. May be repeated every 6–8 weeks if needed.

13. When should I contact my doctor?
Severe abdominal pain, high fever, jaundice, vomiting, or bleeding.

14. Conclusion
TACE is a highly effective, minimally invasive therapy that extends survival and controls tumor growth in patients with unresectable liver cancer.

1. What is Thyroid Artery Embolization?
A minimally invasive procedure that reduces blood supply to thyroid nodules or enlarged thyroid (goiter) by blocking the thyroid arteries, leading to shrinkage.

2. How common is it?
Emerging option for symptomatic benign thyroid nodules or goiter in patients who are poor surgical candidates or prefer to avoid surgery.

3. What are the symptoms?
Neck swelling, difficulty swallowing, breathing issues, cosmetic concerns, or hyperthyroidism symptoms.

4. What are the causes?
Benign nodules (adenomas, colloid goiter), multinodular goiter, or rarely malignancy.

5. Why is proper diagnosis important?
Ultrasound, fine-needle aspiration, and CT/MRI confirm benign nature and vascular anatomy before embolization.

6. Complications if left untreated
Progressive compression symptoms, cosmetic issues, or rare progression to malignancy.

7. How will treatment benefit me?
Reduces nodule/goiter size, relieves compressive symptoms, improves appearance, and avoids open surgery and general anesthesia risks.

8. Treatment options
Observation or medications, Radiofrequency or ethanol ablation, Thyroid artery embolization, Surgical thyroidectomy.

9. How should I prepare for the procedure?
NPO, blood work (thyroid function, coagulation), medication review, and recent imaging.

10. The Procedure: Thyroid Artery Embolization – what to expect
Local anesthesia ± sedation. Catheter via groin or wrist into the thyroid arteries under fluoroscopy. Embolic particles are delivered to reduce blood flow. Procedure takes 1–2 hours.

11. What are the risks?
Neck pain/swelling, transient voice changes, hypothyroidism, infection, and access-site complications.

12. What should I expect after the procedure?
Overnight observation, neck discomfort, possible temporary voice hoarseness, and follow-up ultrasound in weeks to months to assess shrinkage.

13. When should I contact my doctor?
Severe neck swelling, difficulty breathing, voice changes, fever, or bleeding.

14. Conclusion
Thyroid artery embolization is a safe, minimally invasive alternative that effectively reduces thyroid nodule or goiter size while preserving thyroid function in many patients.

1. What is TIPS / DIPS?
Transjugular intrahepatic portosystemic shunt (TIPS) or direct intrahepatic portocaval shunt (DIPS) creates an artificial channel between the portal and hepatic veins to reduce portal pressure.

2. How common is it?
Standard treatment for refractory portal hypertension complications (variceal bleeding, ascites) in cirrhosis patients.

3. What are the symptoms?
Recurrent variceal bleeding, refractory ascites, hepatic hydrothorax, or hepatorenal syndrome.

4. What are the causes?
Cirrhosis (alcohol, hepatitis, NASH) leading to increased portal pressure and portosystemic shunting.

5. Why is proper diagnosis important?
Ultrasound, CT, or endoscopy confirms portal hypertension and varices. TIPS is indicated when medical/endoscopic therapy fails.

6. Complications if left untreated
Life-threatening bleeding, tense ascites, infection, or liver/kidney failure.

7. How will treatment benefit me?
Rapidly lowers portal pressure, controls bleeding and ascites, improves quality of life, and bridges to transplant.

8. Treatment options
Medical therapy + endoscopic variceal ligation, TIPS / DIPS (interventional radiology), Surgical shunts (rarely performed now), Liver transplantation.

9. How should I prepare for the procedure?
NPO, blood work (coagulation, liver/kidney function), antibiotics, and recent imaging.

10. The Procedure: TIPS – what to expect
General or local anesthesia. Jugular vein access; needle creates tract from hepatic to portal vein under fluoroscopy. Covered stent deployed to maintain shunt. Procedure takes 1–3 hours.

11. What are the risks?
Hepatic encephalopathy, liver failure, shunt stenosis/occlusion, infection, and bleeding.

12. What should I expect after the procedure?
ICU or step-down monitoring, encephalopathy management, follow-up ultrasound, and lifelong monitoring of liver function.

13. When should I contact my doctor?
Confusion (encephalopathy), recurrent bleeding/ascites, fever, or jaundice.

14. Conclusion
TIPS/DIPS is a life-saving, minimally invasive procedure that effectively manages complications of portal hypertension in cirrhosis.

1. What is Central Vein Stenosis (CVS)?
Narrowing of the large central veins (subclavian, brachiocephalic, or superior vena cava) that drain blood from the upper body, often due to long-term catheters or dialysis access.

2. How common is it?
Very common in patients with long-term central venous catheters or dialysis accesses (up to 30–50% in some populations).

3. What are the symptoms?
Arm swelling, facial swelling, collateral vein development on the chest, or dialysis access dysfunction.

4. What are the causes?
Endothelial injury from catheters, pacemakers, or high-flow dialysis accesses; thrombosis and fibrosis.

5. Why is proper diagnosis important?
Venography or CT venography confirms the location and severity. Early intervention preserves dialysis access and relieves symptoms.

6. Complications if left untreated
Complete occlusion, loss of dialysis access, chronic swelling, and superior vena cava syndrome.

7. How will treatment benefit me?
Restores blood flow, reduces swelling, prolongs access life, and improves comfort.

8. Treatment options
Balloon angioplasty (often first-line), Stenting for elastic or recurrent lesions, Surgical bypass in refractory cases.

9. How should I prepare for the procedure?
NPO, blood work, medication review, and recent imaging.

10. The Procedure: Central Vein Angioplasty/Stenting – what to expect
Local anesthesia ± sedation. Access via arm or neck vein; catheter advanced to the stenosis under fluoroscopy. Balloon inflation and/or stent placement restores flow. Procedure takes 1–2 hours.

11. What are the risks?
Vessel rupture, stent migration, infection, restenosis, and access complications.

12. What should I expect after the procedure?
Short observation, arm elevation, anticoagulation or antiplatelet therapy, and follow-up imaging.

13. When should I contact my doctor?
Recurrent swelling, pain, or access dysfunction.

14. Conclusion
Endovascular angioplasty and stenting provide effective, minimally invasive treatment for central vein stenosis with excellent immediate results.

1. What is Transjugular Liver Biopsy?
A minimally invasive biopsy performed via the jugular vein to obtain liver tissue samples when percutaneous biopsy is high-risk (coagulopathy, ascites).

2. How common is it?
Common in patients with advanced liver disease, coagulopathy, or ascites who need histologic diagnosis.

3. What are the symptoms?
Signs of liver disease: jaundice, ascites, easy bruising, fatigue, or confusion.

4. What are the causes?
Cirrhosis from various etiologies (alcohol, viral hepatitis, NASH, autoimmune, etc.).

5. Why is proper diagnosis important?
Biopsy confirms etiology, stage of fibrosis, and guides treatment (e.g., transplant candidacy, specific therapies).

6. Complications if left untreated
Delayed diagnosis leading to inappropriate management or progression of liver disease.

7. How will treatment benefit me?
Provides safe tissue diagnosis in high-risk patients, enabling accurate treatment planning.

8. Treatment options
Transjugular liver biopsy (when percutaneous is contraindicated), Percutaneous biopsy (standard when safe), Non-invasive fibrosis assessment (FibroScan, blood tests).

9. How should I prepare for the procedure?
NPO, blood work (coagulation), medication review, and informed consent.

10. The Procedure: Transjugular Liver Biopsy – what to expect
Local anesthesia ± sedation. Catheter inserted via jugular vein into the hepatic vein under fluoroscopy. A biopsy needle obtains multiple core samples. Procedure takes 30–60 minutes.

11. What are the risks?
Bleeding (much lower than percutaneous), infection, arrhythmia, and capsular perforation (rare).

12. What should I expect after the procedure?
4–6 hours observation, neck pressure bandage, mild discomfort, and discharge same day or next day.

13. When should I contact my doctor?
Neck swelling, severe pain, bleeding, shortness of breath, or fever.

14. Conclusion
Transjugular liver biopsy is a safe, effective alternative that provides diagnostic tissue samples in patients where standard percutaneous biopsy is too risky.